HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Manuel Salto-Tellez Selected Research

Core Binding Factor Alpha 3 Subunit

10/2010Lack of RUNX3 inactivation in columnar cell lesions of breast.
2/2009RUNX3 inactivation in colorectal polyps arising through different pathways of colonic carcinogenesis.
1/2009RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
3/2007Targets of genome copy number reduction in primary breast cancers identified by integrative genomics.
7/2006RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Manuel Salto-Tellez Research Topics

Disease

88Neoplasms (Cancer)
12/2021 - 01/2003
31Colorectal Neoplasms (Colorectal Cancer)
01/2022 - 04/2008
30Breast Neoplasms (Breast Cancer)
06/2021 - 01/2003
12Stomach Neoplasms (Stomach Cancer)
05/2016 - 09/2005
10Colonic Neoplasms (Colon Cancer)
07/2021 - 09/2008
10Adenocarcinoma
01/2020 - 01/2010
7Carcinoma (Carcinomatosis)
05/2016 - 11/2007
6Inflammation (Inflammations)
01/2021 - 07/2005
6Neoplasm Metastasis (Metastasis)
01/2021 - 01/2010
5Prostatic Neoplasms (Prostate Cancer)
01/2018 - 01/2010
5Hepatocellular Carcinoma (Hepatoma)
05/2015 - 07/2008
4Microsatellite Instability
01/2022 - 01/2016
4Lung Neoplasms (Lung Cancer)
01/2020 - 01/2007
4Carcinogenesis
04/2012 - 09/2008
3Bites and Stings (Sting)
06/2021 - 01/2017
3Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
04/2020 - 10/2011
3Sarcoma (Soft Tissue Sarcoma)
01/2020 - 12/2008
3Astrocytoma (Pilocytic Astrocytoma)
09/2018 - 10/2006
3Genomic Instability
05/2014 - 05/2011
3Lymphoma (Lymphomas)
03/2011 - 10/2008
2Disease Progression
10/2020 - 09/2018
2Hypoxia (Hypoxemia)
10/2020 - 05/2015
2Neuroblastoma
08/2017 - 11/2013
2Necrosis
12/2014 - 02/2009
2Ovarian Neoplasms (Ovarian Cancer)
08/2011 - 01/2010
2Hyperplasia
07/2011 - 10/2010
2Metaplasia
06/2011 - 05/2011
2Noninfiltrating Intraductal Carcinoma (DCIS)
10/2010 - 01/2009
2Ductal Carcinoma
10/2010 - 01/2009
2Fibrosis (Cirrhosis)
11/2009 - 12/2004
2Adenoma (Adenomas)
02/2009 - 09/2008
2Hyperglycemia
01/2009 - 01/2009
2Teratoma (Teratoid Tumor)
01/2009 - 01/2009
1COVID-19
07/2021
1Hereditary Nonpolyposis Colorectal Neoplasms (Hereditary Nonpolyposis Colorectal Cancer)
02/2021
1Esophageal Neoplasms (Esophageal Cancer)
01/2021

Drug/Important Bio-Agent (IBA)

42Proteins (Proteins, Gene)FDA Link
12/2021 - 01/2003
32Biomarkers (Surrogate Marker)IBA
12/2021 - 01/2003
17DNA (Deoxyribonucleic Acid)IBA
01/2021 - 01/2007
10Biological ProductsIBA
01/2021 - 11/2003
10Messenger RNA (mRNA)IBA
10/2020 - 07/2006
9ErbB Receptors (EGF Receptor)IBA
08/2017 - 11/2007
8RNA (Ribonucleic Acid)IBA
12/2021 - 06/2013
8Formaldehyde (Formol)FDA Link
10/2020 - 01/2010
8Transcription Factors (Transcription Factor)IBA
03/2014 - 07/2006
7ParaffinIBA
10/2020 - 01/2010
5Estrogen ReceptorsIBA
06/2021 - 01/2003
5Pharmaceutical PreparationsIBA
01/2019 - 07/2005
5Small Interfering RNA (siRNA)IBA
03/2014 - 11/2009
5Core Binding Factor Alpha 3 SubunitIBA
10/2010 - 07/2006
4Immune Checkpoint InhibitorsIBA
01/2021 - 01/2016
4Cadherins (E-Cadherin)IBA
05/2016 - 11/2009
4Fluorouracil (Carac)FDA LinkGeneric
02/2014 - 03/2011
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2014 - 11/2003
4Progesterone Receptors (Progesterone Receptor)IBA
01/2010 - 01/2003
3Eosine Yellowish-(YS) (Eosin)IBA
01/2022 - 09/2015
3ChemokinesIBA
01/2021 - 06/2016
3Nucleic AcidsIBA
07/2019 - 12/2013
3EnzymesIBA
03/2019 - 07/2012
3Phosphotransferases (Kinase)IBA
01/2016 - 10/2008
3Trastuzumab (Herceptin)FDA Link
03/2015 - 04/2003
3Hydrogen Sulfide (Sulfide, Hydrogen)IBA
03/2013 - 07/2005
3matrigelIBA
01/2012 - 07/2006
2PlatinumIBA
01/2021 - 11/2019
2B7-H1 AntigenIBA
04/2020 - 01/2016
2Cyclooxygenase 2 (Cyclooxygenase-2)IBA
03/2019 - 04/2017
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2017 - 04/2008
2Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
01/2017 - 05/2016
2GelsolinIBA
05/2016 - 01/2012
2Indicators and Reagents (Reagents)IBA
03/2016 - 11/2007
2LipidsIBA
03/2015 - 02/2010
2Metalloproteases (Metalloproteinases)IBA
09/2014 - 10/2011
2LigandsIBA
05/2014 - 11/2009
2PPAR gammaIBA
05/2014 - 11/2009
2Tyrosine Kinase InhibitorsIBA
11/2013 - 10/2011
2GYY 4137IBA
03/2013 - 07/2009
2Androgen Receptors (Androgen Receptor)IBA
07/2012 - 01/2010
2Hormones (Hormone)IBA
01/2010 - 10/2008
2Transforming Growth Factor beta (TGF-beta)IBA
12/2009 - 09/2005
2Cyclin-Dependent Kinases (cdk Proteins)IBA
11/2009 - 02/2009
2LipopolysaccharidesIBA
07/2009 - 07/2005
2Monoclonal AntibodiesIBA
01/2009 - 09/2005
2Streptozocin (Streptozotocin)FDA Link
01/2009 - 01/2009
1Hematoxylin (Haematoxylon)IBA
01/2022
1CathelicidinsIBA
09/2021
1VaccinesIBA
07/2021
1SuspensionsIBA
07/2021
1InterferonsIBA
06/2021
1Oxaliplatin (Eloxatin)FDA LinkGeneric
01/2021
1Adenosine (Adenocard)FDA LinkGeneric
01/2021
1cyclic guanosine monophosphate-adenosine monophosphateIBA
01/2021
1Calcibiotic Root Canal SealerIBA
10/2020

Therapy/Procedure

26Therapeutics
06/2021 - 01/2003
12Drug Therapy (Chemotherapy)
01/2021 - 07/2008
4Adjuvant Chemotherapy
10/2018 - 01/2016
3Immunotherapy
06/2021 - 01/2016
3Precision Medicine
01/2020 - 12/2008
3Transplantation
05/2014 - 01/2009
2Neoadjuvant Therapy
11/2019 - 03/2019
2Lasers (Laser)
06/2011 - 12/2007